For example, in phase 1 clinical trials, patients with PIK3CA-aberrant cancer had a higher clinical response rate to treatment with PI3K/AKT/mTOR inhibitors than patients who lacked these aberrations [52,53]. This evidence concerns the gene AKT1 and cancer.